• Waleed Mohamed Serag, Magdy Mahmoud Mohamed, Basem Eysa Elsayed, and Sara Mahmoud Abd-Elhamed.
• Department of Chemistry, Faculty of Science, Suez University, Suez, Egypt
• Turk J Med Sci. 2019 Aug 8; 49 (4): 114511501145-1150.

Background/AimHepatitis B virus (HBV) infection is the leading cause of liver fibrosis (LF). The prognosis and management of patients with chronic hepatitis B virus depend on the amount and progression of liver fibrosis. Angiopoietin-like protein 2 (Angptl2) is not only a chronic inflammatory mediator, but also a tissue-remodeling factor. The aim of this study is to explore the predictive value of Angptl2 in different fibrosis stages in patients chronically infected with HBV.Materials And MethodsEighty patients with chronic HBV infection undergoing Fibroscan were included. Serum concentrations of Angptl2 were detected using a commercial ELISA kit.ResultsAngptl2 levels were significantly associated with liver fibrosis stages (P = 0.02). The area under the curve (AUC) of Angptl2 for distinguishing patients who showed significant fibrosis (F2–F4) was70.2%. Angptl2 with fibrosis-4 (FIB-4) and Angptl2 with AST/platelets ratio (APRI) performed best with an AUC of 92.5%.ConclusionIn patients with chronic HBV infection, Angptl2 level represents a potential biomarker independently associated with fibrosis stages. The combination of Angptl2 with FIB-4 or Angptl2 with APRI performed better than the existing models for diagnosing significant fibrosis.This work is licensed under a Creative Commons Attribution 4.0 International License.

28 keywords...

hide…